Dr. Martens (DOCS) Competitors GBX 90.65 +1.10 (+1.23%) As of 08/29/2025 12:14 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesBuy This Stock DOCS vs. VTY, TEM, RMG, SPT, GEN, WIX, YOU, CNIC, SLP, and SRADShould you be buying Dr. Martens stock or one of its competitors? The main competitors of Dr. Martens include Vistry Group (VTY), Templeton Emerging Markets Investment Trust (TEM), Royal Mail (RMG), Spirent Communications (SPT), Genuit Group (GEN), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Sylvania Platinum (SLP), and Stelrad Group (SRAD). These companies are all part of the "computer software" industry. Dr. Martens vs. Its Competitors Vistry Group Templeton Emerging Markets Investment Trust Royal Mail Spirent Communications Genuit Group Wickes Group YouGov CentralNic Group Sylvania Platinum Stelrad Group Dr. Martens (LON:DOCS) and Vistry Group (LON:VTY) are both consumer cyclical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation. Do institutionals & insiders have more ownership in DOCS or VTY? 34.7% of Dr. Martens shares are held by institutional investors. Comparatively, 68.4% of Vistry Group shares are held by institutional investors. 2.8% of Dr. Martens shares are held by company insiders. Comparatively, 10.5% of Vistry Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to DOCS or VTY? In the previous week, Vistry Group had 4 more articles in the media than Dr. Martens. MarketBeat recorded 5 mentions for Vistry Group and 1 mentions for Dr. Martens. Vistry Group's average media sentiment score of 1.03 beat Dr. Martens' score of 0.65 indicating that Vistry Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Martens 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vistry Group 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, DOCS or VTY? Dr. Martens has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Vistry Group has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Do analysts rate DOCS or VTY? Dr. Martens presently has a consensus price target of GBX 6,000, suggesting a potential upside of 6,518.86%. Vistry Group has a consensus price target of GBX 631, suggesting a potential upside of 3.31%. Given Dr. Martens' stronger consensus rating and higher possible upside, equities research analysts plainly believe Dr. Martens is more favorable than Vistry Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Martens 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Vistry Group 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is DOCS or VTY more profitable? Dr. Martens has a net margin of 7.89% compared to Vistry Group's net margin of 6.90%. Dr. Martens' return on equity of 18.91% beat Vistry Group's return on equity.Company Net Margins Return on Equity Return on Assets Dr. Martens7.89% 18.91% 8.12% Vistry Group 6.90%7.69%3.43% Which has better earnings and valuation, DOCS or VTY? Vistry Group has higher revenue and earnings than Dr. Martens. Vistry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Martens£787.60M1.11£68.97M£0.0118,130.00Vistry Group£3.78B0.52£245.05M£0.222,801.83 SummaryVistry Group beats Dr. Martens on 8 of the 15 factors compared between the two stocks. Get Dr. Martens News Delivered to You Automatically Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOCS vs. The Competition Export to ExcelMetricDr. MartensFootwear & Accessories IndustryCyclical SectorLON ExchangeMarket Cap£897.07M£8.56B£3.97B£2.74BDividend Yield2.74%1.84%3.52%5.31%P/E Ratio18,130.001,525.83506.225,113.24Price / Sales1.1142.41250.85101,237.66Price / Cash14.2920.2831.1627.93Price / Book2.403.583.596.89Net Income£68.97M£168.67M£264.31M£5.89B7 Day Performance-0.55%3.10%-0.12%0.15%1 Month Performance11.84%5.50%0.26%49.58%1 Year Performance25.99%-2.54%37.47%153.39% Dr. Martens Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOCSDr. Martens1.6972 of 5 starsGBX 90.65+1.2%GBX 6,000+6,518.9%+26.9%£897.07M£787.60M18,130.00890Positive NewsDividend CutVTYVistry Group1.3812 of 5 starsGBX 644.40+2.0%GBX 631-2.1%-54.6%£2.11B£3.55B8.564,400News CoveragePositive NewsTEMTempleton Emerging Markets Investment TrustN/AGBX 200.50+0.4%N/A+24.4%£2.10B£160.96M16.08N/ANews CoveragePositive NewsRMGRoyal MailN/AN/AN/AN/A£1.98B£12.71B339.34100News CoverageSPTSpirent Communications2.28 of 5 starsGBX 196.60+0.1%GBX 236+20.0%+9.6%£1.41B£561.21M106.281,526News CoverageGENGenuit Group1.8351 of 5 starsGBX 367.50+1.5%GBX 506.67+37.9%-25.5%£911.51M£553.28M38.562,700WIXWickes Group0.8133 of 5 starsGBX 216-0.2%GBX 215-0.5%+17.7%£511.42M£1.45B17.465,930News CoverageAnalyst DowngradeYOUYouGov3.618 of 5 starsGBX 327+2.0%GBX 662.50+102.6%-32.2%£382.64M£335.28M-166.651,820Insider TradeCNICCentralNic GroupN/AN/AN/AN/A£339.82M£790.04M-12,660.00100SLPSylvania Platinum2.4814 of 5 starsGBX 76.20+2.3%GBX 93+22.0%+39.7%£245.92M£99.97M35.71160Positive NewsSRADStelrad Group1.7841 of 5 starsGBX 170+1.8%GBX 200+17.6%+16.2%£225.85M£306.97M14.612,960 Related Companies and Tools Related Companies Vistry Group Alternatives Templeton Emerging Markets Investment Trust Alternatives Royal Mail Alternatives Spirent Communications Alternatives Genuit Group Alternatives Wickes Group Alternatives YouGov Alternatives CentralNic Group Alternatives Sylvania Platinum Alternatives Stelrad Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:DOCS) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Martens plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Martens With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
